Project Grant R43ES032516
- This $500,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program aims to develop a novel human stem cell-based microfluidic developmental toxicology platform. The University of Michigan will receive funding from September 2022 to August 2024 to conduct technological development of a repeatable, controllable, high-throughput microfluidic system for generating three-dimensional multicellular organoid models for toxicity testing. The platform seeks...
- Federal Project Grant Award Summary Millennium Bioresearch, Inc. (doing business as MB Research Laboratories) received a $259,274 Project Grant from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health program (CFDA 93.113) for the period July 1, 2026 through June 30, 2027. The award supports development of the Egg LD50 Assay for Categorization (ELDAC), an in vitro alternative testing methodology designed to replace traditional mammalian acute oral...
- The National Institute of Environmental Health Sciences (NIEHS) awarded University of Hawaii at Manoa a Project Grant of $156,500 under the Environmental Health program (CFDA 93.113) on April 9, 2026, with completion anticipated by April 8, 2028. This grant supports the development and validation of new approach methodologies (NAMs) for developmental and reproductive toxicity (DART) assessment using morphogenesis models derived from pluripotent stem cells. The project deliverables include...
- This $1,044,855 Project Grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund Nemalife Inc. to deliver high-throughput testing of anti-aging and FDA-approved drugs in genetically diverse invertebrate Alzheimer's disease models. Under the Aging Research program (CFDA 93.866), the awardee will screen 300 anti-aging compounds and 200 FDA drugs to identify candidates that improve neuronal aging and protect against protein misfolding diseases...
- This Project Grant award from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) provides $270,428 to TEO Therapeutics Incorporated, a small disadvantaged business, to develop a biomimetic platform for more efficient pharmaceutical drug development in oncology. The key products and services to be delivered include: Refining and testing a proof-of-concept hardware product line for a Shell-Free Quail Xenograft Assay, optimizing throughput and assessing...
- Federal Project Grant Award Summary Attogene Corporation received a $257,312 Project Grant from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health program (CFDA 93.113), awarded on August 26, 2025, with a completion date of December 31, 2026. The award supports the development of a novel electrochemical biosensor designed to rapidly detect organophosphate and carbamate (OPAC) pesticide residues in environmental and food samples. The biosensor...
- Grant Award Summary The National Institute of Environmental Health Sciences (NIEHS) awarded Johns Hopkins University a $310,500 Project Grant (CFDA 93.113: Environmental Health) on August 22, 2025, to support research software engineering and infrastructure development for the Caenorhabditis Natural Diversity Resource (CAENDR). Under the direction of Dr. Erik Andersen, Research Software Engineer Dr. Michael Sauria will oversee the integration, optimization, and expansion of computational tools...
- Amelia Technologies LLC received a $303,165 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health program (CFDA 93.113), with an award date of August 19, 2025 and completion date of July 31, 2026. The award supports the development and advancement of SphereDNA, a novel high-throughput genotoxicity screening platform that addresses critical gaps in toxicity assessment for engineered nanomaterials (ENMs). SphereDNA utilizes...
- Grant Award Summary The National Institute on Aging (NIA) awarded a Project Grant of $556,121 to Washington University's Office of Sponsored Research Services, effective January 15, 2026, through December 31, 2030, under the Aging Research program (CFDA 93.866). The research project investigates transgenerational epigenetic adaptation of longevity changes in response to repeated environmental stresses. Specifically, the funded research will examine how successive generational exposures to...
- Summary The National Institutes of Health (NIH) Office of the Director awarded a $3.12 million Cooperative Agreement (CFDA 93.310, Trans-NIH Research Support) to Texas A&M Agrilife Research, effective March 2, 2026, through December 31, 2030, to establish the NAMS-Decisions Center for integrating New Approach Methodologies (NAMs) into regulatory decision-making for chemical safety assessment. The center delivers defined approaches for using in vitro and in silico NAMs to enhance...
A NOVEL TECHNOLOGY TO ASSESS CHRONIC TOXICITY IN GENETICALLY DIVERSE NEMATODE POPULATIONS - PROJECT ABSTRACT THE NUMBER OF NEW PRODUCTS SUCH AS DRUGS, COSMETICS AND FOOD ADDITIVES INTRODUCED INTO THE MARKET IS GROWING AND POSES A SIGNIFICANT CHALLENGE FOR RISK PREDICTION. CURRENTLY, VERTEBRATE TESTING IS THE INDUSTRY STANDARD FOR HAZARD ASSESSMENT BUT HAS LIMITATIONS INCLUDING HIGH COSTS, AND THE GROWING PUBLIC AND CORPORATE SENTIMENT AGAINST USING VERTEBRATES FOR CHEMICAL TESTING. IMPORTANTLY, CURRENT TOXICITY ASSESSMENT DOES NOT INCORPORATE GENETIC DIVERSITY LEADING TO FAILURE OF DRUG CANDIDATES AND UNINTENDED RISKS TO HUMAN SUB-POPULATIONS. THE CELEBRATED INVERTEBRATE MODEL C. ELEGANS HAS THE POTENTIAL TO FILL THIS GAP SINCE THOUSANDS OF GENETICALLY DIVERSE NEMATODE POPULATIONS ARE AVAILABLE. HOWEVER, THE MAIN CHALLENGE IS THAT CHRONIC STUDIES OF CHEMICALS IN THE NEMATODE MODEL IS STILL TEDIOUS, PRECLUDING LARGE-SCALE TOXICITY TESTING IN NEMATODE POPULATIONS. THIS PROPOSAL AIMS TO DEVELOP A HIGH-THROUGHPUT TECHNOLOGY FOR CHRONIC TOXICITY SCREENING OF DIVERSE GENETIC POPULATIONS IN ADULT C. ELEGANS. THE FOCUS OF OUR PHASE I PLAN IS TO PURSUE CHRONIC TOXICITY STUDIES ON SELECT TOXINS AND GENERATE FOUNDATIONAL DATA HIGHLIGHTING THE IMPACT OF GENETIC DIVERSITY, AND SUBSEQUENTLY SCALE THE NEMALIFE TECHNOLOGY TO ENABLE LARGE-SCALE GENETIC DIVERSITY SCREENING. AIM 1: TO GENERATE CHRONIC DOSE-RESPONSE DATA ON TOXINS AFFECTING DIVERSE C. ELEGANS STRAINS. WE WILL TEST THE EFFECTS OF FIVE TOXINS FOR WHICH WE KNOW THE VARIABILITY IN HUMAN AND RODENT RESPONSES. ANIMALS WILL BE EXPOSED TO TOXINS DAILY, FOLLOWED BY SCORING OF SURVIVAL, REPRODUCTIVE AND NEUROMUSCULAR HEALTH. ABOUT 1200 WHOLE-LIFE ASSAYS WILL BE CONDUCTED WITH DATA ACQUIRED ON 500+ ANIMALS PER ASSAY CONDITION. WE WILL GENERATE DATA THAT WILL DEFINE THE RANK-ORDER OF C. ELEGANS TOXIN RESPONSE VIS-A-VIS MAMMALIAN SYSTEMS, OPTIMIZE PHENOTYPING CONDITIONS FOR LARGE NUMBERS OF STRAINS PER SPECIES, AND DEFINE THE AMOUNT OF HERITABLE VARIATION IN TOXIN RESPONSES. THESE PILOT DATA WILL VALIDATE THE CAPABILITIES AFFORDED BY OUR SCREENING PLATFORM. AIM 2: TO SCALE THE THROUGHPUT OF NEMALIFE TECHNOLOGY FOR THOUSANDS OF CHRONIC TOXICITY ASSAYS. CURRENTLY, NEMALIFE'S TECHNOLOGY HAS A THROUGHPUT OF HUNDREDS OF CHRONIC TOXICITY ASSAYS. HOWEVER, GIVEN THE LARGE NUMBER OF TOXINS AND VAST LIBRARY OF GENETIC STRAINS AND WILD ISOLATES AVAILABLE, THERE IS A SIGNIFICANT NEED TO INCREASE THE THROUGHPUT OF OUR TECHNOLOGY. THEREFORE, WE WILL DEVELOP THE TECHNOLOGY INFRASTRUCTURE AND WORKFLOW TO SCALE THE THROUGHPUT WHICH INCLUDES MULTIPLEXING OUR APPROACH, SCALE-UP OF CHIP FABRICATION AND STREAMLINING DATA ANALYSIS. TECHNOLOGY DEVELOPMENT AT THE SCALE OF THOUSANDS OF WHOLE-LIFE TOXICITY ASSAYS IN A FEW WEEKS WITH READOUTS ON ANIMAL DEATH AND NEUROMUSCULAR IMPAIRMENTS WILL BE A MAJOR BREAKTHROUGH IN THE FIELD OPENING UP NEW BUSINESS OPPORTUNITIES IN TOXICITY TESTING IN THE DRUG AND CONSUMER INDUSTRY.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 5/16/23 | ||
| Not listed | $0 | 5/16/23 | ||
| Not listed | $0 | 5/15/23 | ||
| Not listed | $0 | 12/2/21 | ||
| Not listed | $0 | 12/2/21 |